Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:60592 |
Name | B-cell adult acute lymphocytic leukemia |
Definition | An adult acute lymphoblastic leukemia occurring in adults and that has_material_basis_in B lymphocytes. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia adult acute lymphocytic leukemia B-cell adult acute lymphocytic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FLT3 E598_Y599insFDFREYE FLT3 R845G | Quizartinib | B-cell adult acute lymphocytic leukemia | sensitive | detail... |
FLT3 E598_Y599insFDFREYE FLT3 R845G | Crenolanib | B-cell adult acute lymphocytic leukemia | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Active, not recruiting | USA | ITA | FRA | ESP | BEL | 12 |
NCT02877303 | Phase II | Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab + Inotuzumab ozogamicin Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ofatumumab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine Sulfate | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT02924402 | Phase I | XmAb13676 | Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies | Recruiting | USA | FRA | 2 |
NCT03642626 | Phase II | Cyclophosphamide + Fludarabine + Tisagenlecleucel axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Recruiting | USA | 0 |
NCT03913559 | Phase II | Inotuzumab ozogamicin Cytarabine + Hydrocortisone + Methotrexate Acetaminophen + Diphenhydramine + Methylprednisolone | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03962465 | Phase I | Daunorubicin + Inotuzumab ozogamicin + Pegaspargase + Prednisone + Vincristine Sulfate Daunorubicin + Inotuzumab ozogamicin + Prednisone + Vincristine Sulfate Cytarabine Methotrexate | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001) | Recruiting | USA | 0 |
NCT04170283 | Phase III | Zanubrutinib | Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies | Enrolling by invitation | USA | ITA | FRA | ESP | DEU | 9 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | FRA | ESP | DEU | BEL | 1 |
NCT04803123 | Phase I | Copanlisib | Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL | Recruiting | USA | 0 |